Home

Rockwell Medical Appoints Joe Dawson to the Company's Board of Directors

via Business Wire

Rockwell Medical, Inc. (the "Company") (Nasdaq: RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that the Company appointed Joe Dawson to its board of directors. Additionally, Andrea Heslin Smiley has resigned from the Company's board of directors to pursue other endeavors.

"We are pleased to welcome Joe to Rockwell Medical's board of directors. Joe is a seasoned executive who has extensive operational experience, a strong network in the renal care space, and deep domain expertise in building and scaling commercial organizations," said Robert S. Radie, Chairman of the Board of Directors at Rockwell Medical. "Additionally, on behalf of the Company and its board of directors, I would like to thank Andi for her five years of service and wish her continued success in her future ventures."

Throughout his career, Mr. Dawson has negotiated and secured key customer contracts, acquired companies in new product segments, and driven top- and bottom-line growth. Additionally, his mastery of FDA-regulated markets, global supply chains, and commercialization pathways for medical devices make him an invaluable addition to Rockwell Medical's board of directors as the Company seeks to grow its market share, optimize its manufacturing networks, and pursue business development opportunities.

Mr. Dawson has more than 25 years' experience in the renal care and cardiovascular markets. Most recently, he was President, North America Division at Nipro Medical Corporation, a wholly owned subsidiary of Nipro Corporation. Overseeing one of the largest global medical device manufacturer's U.S. operations, Mr. Dawson's leadership included strategic P&L responsibility, operational oversight, and direct accountability for compliance in highly regulated therapeutic categories including dialysis, vascular access, and infusion technologies. Previously, he held various sales and management positions at Cordis Corporation, a Johnson & Johnson subsidiary at the time and leading developer and manufacturer of interventional vascular technology, specializing in cardiology and endovascular devices like catheters, balloons and stents. Mr. Dawson began his career at W. L. Gore & Associates, a global materials science company known for its innovative products, particularly those made from expanded polytetrafluoroethylene. Mr. Dawson earned a B.S. in Neurobiology from St. John's University.

About Rockwell Medical

Rockwell Medical, Inc. (Nasdaq: RMTI) is a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products for dialysis providers worldwide. Rockwell Medical's mission is to provide dialysis clinics and the patients they serve with the highest quality products supported by the best customer service in the industry. Rockwell is focused on innovative, long-term growth strategies that enhance its products, its processes, and its people, enabling the Company to deliver exceptional value to the healthcare system and provide a positive impact on the lives of hemodialysis patients. Hemodialysis is the most common form of end-stage kidney disease treatment and is typically performed in freestanding outpatient dialysis centers, hospital-based outpatient centers, skilled nursing facilities, or a patient’s home. Rockwell Medical's products are vital to vulnerable patients with end-stage kidney disease, and the Company is relentless in providing unmatched reliability and customer service. Certified as a Great Place to Work® in 2023, 2024 and 2025, and named Fortune Best Workplaces in Manufacturing & Production™ in 2024 and 2025, Rockwell Medical is Driven to Deliver Life-Sustaining Dialysis Solutions™. For more information, visit www.rockwellmed.com.

Forward-Looking Statements

Certain statements in this press release may constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as, "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "could," "can," "would," "develop," "plan," "potential," "predict," "forecast," "project," "intend," "look forward to," "remain confident," “are determined,” “are on track,” “are resolute in our vision,” "work to," "drive towards," “focused on,” “seeks to” or the negative of these terms, and similar expressions, or statements regarding intent, belief, or current expectations, are forward looking statements. Such statements include statements relating to the Company growing its market share, optimizing its manufacturing networks, and pursuing business development opportunities. While Rockwell Medical believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties (including, without limitation, those set forth in Rockwell Medical's SEC filings), many of which are beyond our control and subject to change. Actual results could be materially different. Risks and uncertainties include, but are not limited to those risks more fully discussed in the "Risk Factors" section of our Annual Report on Form 10-K for the year ended December 31, 2024, as such description may be amended or updated in any future reports we file with the SEC. Rockwell Medical expressly disclaims any obligation to update our forward-looking statements, except as may be required by law.

$RMTI appoints Joe Dawson to the Company's Board of Directors. Joe is a seasoned executive who has extensive operational experience, a strong network in the renal care space, and deep domain expertise in building and scaling commercial organizations.

Contacts